• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Bristol Myers, Pfizer score another win in their Eliquis patent defense, protecting the...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 07, 2021 at 11:02: PM
via The U.S. Court of Appeals for the Federal Circuit has upheld a prior win for the companies covering two Eliquis patents—the drug’s composition of matter patent and a formulation patent. While the case is subject to another potential appeal, this appeals win sets the companies up to retain U.S. exclusivity until April 1, 2028.

article source
 




Top Bottom
Back
Quote